Vaccine makers meet WTO D-G, flag excess capacity of Covid-19 jabs

Some manufacturers also said that the regulatory approval framework for Covid-19 vaccines in other nations also takes a substantial amount of time

WTO D-G
Director-General of WTO Ngozi Okonjo-Iweala during a meeting in New Delhi. (Photo: PTI)
Shreya NandiSohini Das New Delhi/Mumbai
2 min read Last Updated : Oct 22 2021 | 2:14 AM IST
In a meeting with World Trade Organization (WTO) Director-General Ngozi Okonjo-Iweala, the country's top vaccine manufacturers on Thursday raised concerns regarding excess capacity of Covid-19 jabs created during the pandemic.
 
"With the outbreak of the pandemic, vaccine manufacturers have rapidly created capacities to meet demand. Going ahead, manufacturers are concerned about excess capacity and how it can be utilised," said a person in the know, adding that similar concerns have been raised by manufacturers of other countries as well.
 
Okonjo-Iweala, who is on a three-day visit to the national Capital, met key industry leaders, including vaccine makers, such as Bharat Biotech Managing Director (MD) Suchitra Ella, Panacea Biotech MD Rajesh Jain, and Biological E Chief Operating Officer Lakshminarayana Neti, among others.
 
Some manufacturers also said that the regulatory approval framework for Covid-19 vaccines in other nations also takes a substantial amount of time.
 
They urged the D-G if the WTO could help in ways to reduce delay.
 
Vaccine makers are concerned about optimal utilisation of excess capacities created during the pandemic.
 
Ella raised similar concerns at a Federation of Indian Chambers of Commerce & Industry event on Thursday, and pointed out that when the Covid-19 pandemic is gone, what would happen to the excess capacities created.
 
“The excess capacities, manpower recruited... what happens? How many companies will be able to sustain it? It will be a global challenge,” said Ella, adding, “Today we want more production, tomorrow who will want that excess production?”


One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :WTOCoronavirus VaccineBharat BiotechVaccine

Next Story